ArticleClinical cancer research : an official journal of the American Association for Cancer Research2013
Hepatocellular carcinoma from an immunologic perspective.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 92 citations in OpenAlex.
- Feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to locoregional therapies.Cancer science · 2017Trial
- Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma.Journal of hepatology · 2017Trial
- Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients.Journal of immunology research · 2015Trial
- Efficacy of various sequences of transcatheter arterial chemoembolization combined with PD-1 inhibitors in advanced hepatocellular carcinoma: a retrospective analysis.Frontiers in medicine · 2025Article
- Immune checkpoint inhibitor plus tyrosine kinase inhibitor with or without transarterial chemoembolization for unresectable hepatocellular carcinoma.Frontiers in oncology · 2025Article
- Multi-omics analysis of macrophage-associated receptor and ligand reveals a strong prognostic signature and subtypes in hepatocellular carcinoma.Scientific reports · 2024Article
- The Synergistic Effect of Interventional Locoregional Treatments and Immunotherapy for the Treatment of Hepatocellular Carcinoma.International journal of molecular sciences · 2023Review
- Synergizing liver systemic treatments with interventional oncology: friend or foe?The British journal of radiology · 2022Review
- The Treatment Landscape of Advanced Hepatocellular Carcinoma.Current oncology reports · 2022Review
- Impact of Chemoembolic Regimen on Immune Cell Recruitment and Immune Checkpoint Marker Expression following Transcatheter Arterial Chemoembolization in a VX2 Rabbit Liver Tumor Model.Journal of vascular and interventional radiology : JVIR · 2022Article
- Development and Validation of TACE Refractoriness-Related Diagnostic and Prognostic Scores and Characterization of Tumor Microenvironment Infiltration in Hepatocellular Carcinoma.Frontiers in immunology · 2022Article
- Tumor Microenvironment in Hepatocellular Carcinoma: Key Players for Immunotherapy.Journal of hepatocellular carcinoma · 2022Review
- Fine-tuning of regulatory T cells is indispensable for the metabolic steatosis-related hepatocellular carcinoma: A review.Frontiers in cell and developmental biology · 2022Review
- Combined treatments in hepatocellular carcinoma: Time to put them in the guidelines?World journal of gastrointestinal oncology · 2021Review
- Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors and Applicability of First-Line Atezolizumab/Bevacizumab in a Real-Life Setting.Journal of clinical medicine · 2021Review
- Article
- Review
- Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma.Nature reviews. Gastroenterology & hepatology · 2021Review
- Optimizing the Combination of Immunotherapy and Trans-Arterial Locoregional Therapy for Stages B and C Hepatocellular Cancer.Annals of surgical oncology · 2021Review
- Potential therapeutic targets in the tumor microenvironment of hepatocellular carcinoma: reversing the protumor effect of tumor-associated macrophages.Journal of experimental & clinical cancer research : CR · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Hepatocellular carcinoma is the third most common cancer worldwide. It is an inflammation-associated cancer. Multiple investigators have demonstrated that analysis of the tumor microenvironment may be used to predict patient outcome, indicating the importance of local immune responses in this disease. In contrast with other types of cancer, in which surgery, radiation, and systemic cytotoxic chemotherapies dominate the treatment options, in hepatocellular carcinoma locoregional treatments are widely applied. Such treatments induce rapid tumor cell death and antitumor immune responses, which may favor or impair the patients' outcome. Recent immunotherapeutic studies demonstrating promising results include trials evaluating intratumoral injection of an oncolytic virus expressing granulocyte macrophage colony-stimulating factor, glypican-3 targeting treatments, and anti-CTLA4 treatment. Although some of these novel approaches may provide benefit as single agents, there is a clear opportunity in hepatocellular carcinoma to evaluate these in combination with the standard modalities to more effectively harness the immune response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.